Mesoblast Limited (MESO) Stock Forecast and Price Target (2026)

Last updated November 2026

Short answer

There is no meaningful price-target consensus for Mesoblast Limited (MESO): too few analysts publish a target on it for an average to mean anything. Thin coverage is normal for smaller and newer companies and says nothing about the business. What does exist is an earnings forecast. For the fiscal year ending Jun 2027, the 6 analysts publishing estimates on MESO expect earnings of -$0.06 per share and revenue of 245.3 million AUD (+46%). The full quarter and fiscal-year estimates are below, with the drivers and risks that decide whether they are met. Walnut is not an investment adviser.

Why MESO has no consensus price target

Sell-side coverage follows trading volume and banking relationships, so smaller companies, recent listings, and names outside the major indices often carry little or none. MESO is one of them. It says nothing about the quality of the business, but it does mean there is no informed average to anchor to, and that any single target you find elsewhere is one analyst's model.

Mesoblast reports in U.S. dollars under IFRS even though the parent company's functional currency is the Australian dollar, and its fiscal year ends June 30, so figures quoted as fiscal 2026 cover July 2025 through June 2026. At about $13.47 per ADS on October 16, 2026, the stock trades near 14 to 15 times trailing revenue, down from about 17 times in August as the price fell. Analyst coverage is thin: two analysts in Yahoo Finance's data, with consensus expecting a small loss for fiscal 2027 and a first profit (about $0.46 per ADS) in fiscal 2028.

MESO earnings and revenue forecast

For the fiscal year ending Jun 2027, the 6 analysts publishing estimates on MESO expect earnings of -$0.06 per share and revenue of 245.3 million AUD (+46%).

PeriodEPS estimateEPS growthRevenue estimateRevenue growth
Quarter ending Sep 2026
next quarter to report, 1 analyst
-$0.08n/a54.9 million AUDn/a
Quarter ending Dec 2026
the quarter after, 1 analyst
-$0.07n/a57.2 million AUD+33%
Fiscal year ending Jun 2027
fiscal year next to report, 6 analysts
-$0.06
-$0.12 to $0.01
n/a245.3 million AUD
209.3 million AUD to 305.2 million AUD
+46%
Fiscal year ending Jun 2028
the fiscal year after, 6 analysts
$0.46
$0.36 to $0.55
n/a366.1 million AUD
270 million AUD to 464.3 million AUD
+49%

Consensus estimates for MESO published by sell-side analysts, as of November 2026, from Yahoo Finance. Each figure is the average of the analysts counted, with the lowest and highest estimate beneath it; growth compares with the same period a year earlier and is left blank where either figure is a loss. Estimates change constantly. Walnut is not an investment adviser.

Estimates are the most widely published forecast there is: many more analysts model a company's earnings than publish a price target on it. They are also revised constantly, and the direction of those revisions into a report is often more informative than the level. Mesoblast Limited next reports on August 26, 2026, which is when these figures get tested against actual results.

Is there a 2030 forecast for MESO?

Not a published one. Analyst price targets run to about twelve months, occasionally two years, and the firms covering MESO do not put out a 2030 number. Anything presenting one is extrapolating a growth rate of its own, and a figure produced that way tells you about the assumption chosen, not about the company.

What can be said over a long horizon is what the current price already assumes about the business, which is a question the filings answer and a forecast cannot.

For a ten-year question, that frame is more useful. A share price is the market’s estimate of future cash flows discounted to today, so the multiple is already a statement about growth. The long-horizon question is whether Mesoblast Limited can deliver what is priced in, and what would have to change for that to break. Both are answerable from the drivers and risks below. A number for 2030 is not.

What could move MESO from here

In short: the drivers cited most often are Ryoncil's first full year of sales, Label extension into adult graft versus host disease, Rexlemestrocel-L reaching regulatory and trial milestones. The risk cited most often against it is nearly all current revenue comes from a single product in a single small indication, so any manufacturing interruption, reimbursement change or safety signal on Ryoncil would hit the whole business at once.

Both sides are worked through properly, with the high and low targets used as the bull and bear anchors, on the MESO is it a buy page.

Your questions about Mesoblast Limited

Ask Walnut's AI anything about MESO and see how it fits what you own.

FAQ

What is the price target for Mesoblast Limited (MESO)?

+

There is no meaningful consensus price target for MESO, because too few analysts publish on it. Thin coverage is common for smaller and newer companies. Where only one or two analysts cover a stock, an "average target" is really one person's model, so we do not print a number that would imply more agreement than exists. Check your broker's research tab for whatever individual coverage exists.

Is there an analyst forecast for MESO?

+

For earnings, yes; for the share price, not a meaningful one. For the fiscal year ending Jun 2027, the 6 analysts publishing estimates on MESO expect earnings of -$0.06 per share and revenue of 245.3 million AUD (+46%). Fewer analysts publish a price target on MESO than publish earnings estimates, which is common for smaller and newer companies, and a lack of target coverage says nothing about the business itself.

What are analysts' earnings estimates for Mesoblast Limited (MESO)?

+

For the fiscal year ending Jun 2027, the 6 analysts publishing estimates on MESO expect earnings of -$0.06 per share and revenue of 245.3 million AUD (+46%). For the fiscal year ending Jun 2028, the consensus is $0.46 per share. These are consensus estimates as of November 2026, the average of what the covering analysts publish, and they are revised constantly, especially around each earnings report. They describe expectations, not results.

When does MESO report earnings next?

+

Mesoblast Limited's next earnings report is scheduled for August 26, 2026. The report is when the estimates on this page get tested against actual results, which is why targets and estimates tend to move most in the days after it.

What could move MESO?

+

The drivers and the risks are laid out on this page and in more depth on the MESO "is it a buy" page. Without analyst estimates to anchor to, the useful framing is a set of scenarios.

Walnut is informational, not investment advice, and does not publish price targets of its own. The analyst figures on this page come from a November 2026 data pull of published third-party research, are approximate, and change constantly. The share price is the last one Yahoo Finance reported on November 16, 2026, and every percentage against it on this page is measured from that price. Verify current figures with your broker before acting on them.

Forecasts for similar stocks